<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AI Medical Device Compliance Review</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <header>
        <h1>Compliance Review for AI-Enabled Medical Devices</h1>
    </header>
    <main>
        <section id="upload-section">
            <h2>Upload Compliance Questions Document</h2>
            <input type="file" id="wordFile" accept=".docx,.doc">
            <button id="parseBtn">Parse Questions</button>
            <br>
            <input type="checkbox" id="deleteCheckbox"> Delete Parsed Content
        </section>
        <section id="review-section" style="display: none;">
            <h2>Compliance Review Form</h2>
            <form id="reviewForm">
                <div id="questionsContainer">
<section id="section17"><h2>17. Software Risk Management (PD IEC TR 80002-1) ☐ N/A</h2><div class="question"><label>17.0. Is there an impact to Software Risk Manage
ment or other software-specific aspects,</label><textarea placeholder="Provide details"></textarea><p style="color:blue">not already considered? If appropriate, check N/A and leave remaining questions in this section blank. Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>17.1. N Are there software risks that Indicate whether software risk management is</label><textarea placeholder="Provide details"></textarea><p style="color:blue">are defined outside of ISO separately defined. Yes, No. If no, provide 14971? rationale. Software risk management is required as part of IEC 62304 that meet the requirements of ISO 14971. PD IEC/TR 80002-1:2009 provides guidance on the application of ISO 14971 to medical device software. Evidence: Sub-systems shall be defined under procedures, plans, etc. Note: Additional tools for software risk analysis may be defined including Fault Tree Analysis for Top-Down Risk Assessment method. Ref. ISO 31010 and IEC 61025 FTA, IEC 60812 FMEA.</p></div><div class="question"><label>17.2. Are there any new software If yes, where are these documented and have,</label><textarea placeholder="Provide details"></textarea><p style="color:blue">related adverse events, hazards, they been assessed for harm? Update the hazardous situations, or harms Product Level Risk Management where a related to this change? software risk can lead to potential harm of end user(s). Software should be performed on the whole medical device (system), including software, SOUP, AI and hardware and its environment. Software risk management activities should NOT be conducted in isolation from the system. Some activities for risk management © N. St John Lynch, DkIT 2025-2026 Confidential Page 32 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01 may be best performed by software engineers as an integral part of IEC 62304 Software Development Lifecycle and can include software risk identification. Isolation is not accepted where software risks cannot be managed in isolation from the overall medical device risk management due to the interdependence of hardware failures, software failures and risk control measures. Sub-systems shall be defined. Evidence: provide risk analysis documented review/outcomes.</p></div><div class="question"><label>17.3. Probability of occurrence Provide details of how probability of</label><textarea placeholder="Provide details"></textarea><p style="color:blue">methodology should be occurrence is captured or refer to SOP/Plan. appropriate for software. Figure 1 PD IEC TR 80002-1:2009 (current Jan 2026) Note: software engineering rigor per IEC 62304 is defined based on severity.</p></div><div class="question"><label>17.4. Has the list of anomalies, IEC 62304 and ISO 14971 requires full risk</label><textarea placeholder="Provide details"></textarea><p style="color:blue">software bugs or defects been analysis and evaluation. However, software reviewed for risk and escalated anomalies are difficult to evaluate for to product risk management as probability contributing to hazardous appropriate? situations (ref. PD IEC 80002-1), since software does not fail randomly in us. Therefore, the method for evaluating software bugs not be defined under a software-specific risk management process. Integration and escalation points should be defined. Risks arising from software anomalies most often are evaluated based on severity of harm alone. Where potential harm meets the definition of ISO 14971, escalation to product risk analysis is required. © N. St John Lynch, DkIT 2025-2026 Confidential Page 33 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div><div class="question"><label>17.5. SOUP Anomaly List for Risk If Software of Unknown Provenance (SOUP) is</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Management used, active monitoring and evaluating publicly available anomaly lists and information about the SOUP field performance should be planned. Where possible this should be supported by contractual agreement with the SOUP supplier at the time of SOUP acquisition.</p></div><div class="question"><label>17.6. User Interface(s) and Integration Software Graphical / User Interfaces are a</label><textarea placeholder="Provide details"></textarea><p style="color:blue">in a Clinical Setting necessary aspect of a software system that is required to be planned, implemented and iteratively reviewed and assessed for risk, including prior to planned or unplanned changes. Usability engineering (ISO 62366-x) should include software- and AI-related components. The processes shall be defined in the software development plan or relevant plan(s). Note: IEC 80001-1 should be considered for IT networks in a clinical environment with responsibilities delineated between manufacturer and healthcare technician responsible for integration into IT network in a clinical setting.</p></div><div class="question"><label>17.7. Are software checklists or Example questions:</label><textarea placeholder="Provide details"></textarea><p style="color:blue">software safety aspects adequately considered, including - can the safety-related software item gain fault tolerance? access to its processor when needed? - can the safety-related software item be guaranteed enough processor time to complete its task before an unsafe state develops into an accident? - can it be demonstrated that no other software item can corrupt or otherwise interfere with the safety-related software item? - are the development methods adequate to make risks visible to the designer(s) and risk assessor(s) e.g., state machines, UML. - What aspects require fault tolerance design, i.e., ensuring the safety-related functions continue to operate in the presence of component faults, including software anomalies (e.g., by use of redundancy or switch to safe mode). © N. St John Lynch, DkIT 2025-2026 Confidential Page 34 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div></section>                                                                                                                        <section id="section18"><h2>18. AI Risk Management (ISO/DTS-24971-2 2025) ☐ N/A</h2><div class="question"><label>18.0. Does the change impact AI related risk manage
ment or potential risk scenarios? If not</label><textarea placeholder="Provide details"></textarea><p style="color:blue">indicate N/A and leave remaining questions in this section blank. Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>18.1. Apply ISO 14971 risk Apply ISO 14971 risk framework to assessment of</label><textarea placeholder="Provide details"></textarea><p style="color:blue">management to machine- AI-related risks, or provide rationale for equivalent learning medical devices. method. Include ML-specific hazards, drift, bias, data issues, interoperability, accessibility (ref. EU Accessibility Act), etc.</p></div><div class="question"><label>18.2. Are additional resources Ensure ML-specific oversight and review. Provide</label><textarea placeholder="Provide details"></textarea><p style="color:blue">required? appropriate resources to perform risk activities with ML knowledge and, assign competent personnel. Ensure team has ML, data, clinical, usability, cybersecurity expertise</p></div><div class="question"><label>18.3. Has risk policy/plan(s) been Ensure review and acceptability criterion is</label><textarea placeholder="Provide details"></textarea><p style="color:blue">reviewed/updated to take appropriate for AI devices, including those capable account of AI/ML medical of autonomous change. devices including risk acceptability criterion?</p></div><div class="question"><label>18.4. Does the risk management file Risks should cover the full MLMD lifecycle. Include</label><textarea placeholder="Provide details"></textarea><p style="color:blue">require updating, including for ML behaviour, drift, bias, data chain failures, refer consideration of AI risks to ISO/TR 24971 or other appropriate standards for throughout the full lifecycle methods and techniques. Identify AI specific (concept through hazards, ref. Annex B & C (ISO/DTS-24971-2 decommission)? 2025)</p></div><div class="question"><label>18.5. Are there controls in place that Provide details. Define triggers, data collection,</label><textarea placeholder="Provide details"></textarea><p style="color:blue">ensure adequate monitoring, frequency, etc. retraining, update criteria, rollback provisions?</p></div><div class="question"><label>18.6. Is traceability maintained for Include dataset provenance, model versions</label><textarea placeholder="Provide details"></textarea><p style="color:blue">all hazards, controls, testing and information provided to end-user(s).</p></div><div class="question"><label>18.7. Have the AI/ML-specific Document and/or update the Characteristics</label><textarea placeholder="Provide details"></textarea><p style="color:blue">characteristics affecting safety related to safety for AI related risks. Provide been documented? reference to documentation. Include data quality, autonomy, explainability, bias, etc.</p></div><div class="question"><label>18.8. Is the estimate of risk suitable Use severity only where the probability is unknown.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">for AI/ML devices? Consider data representativeness, usability studies. Include ML performance drift & subgroup performance.</p></div><div class="question"><label>18.9. Are controls to hazards Test with synthetic data, demographic bias checks</label><textarea placeholder="Provide details"></textarea><p style="color:blue">adequately verified?</p></div><div class="question"><label>18.10. Evaluate residual risk incl. Are explainability tools verified/validated.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">transparency & explainability Disclosure must include ML limitations. Include © N. St John Lynch, DkIT 2025-2026 Confidential Page 35 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01 performance claims and differences with adequate transparency for user needs. Address transparency as a risk, identifying the risk of too much/too little transparency.</p></div><div class="question"><label>18.11. Evaluate residual risk vs Consider autonomy level, novelty, UI usability,</label><textarea placeholder="Provide details"></textarea><p style="color:blue">benefits representative population, accessibility, etc.</p></div><div class="question"><label>18.12. How are significant residual Significant risks must be communicated. Consider</label><textarea placeholder="Provide details"></textarea><p style="color:blue">risks communicated to each documenting disclaimer notices on reports, etc. to user/stakeholder; update as ensure user(s) including patients understand AI is appropriate. used in the device and to what extent.</p></div><div class="question"><label>18.13. Ensure product risk Document Risk Management Plan, Analyses,</label><textarea placeholder="Provide details"></textarea><p style="color:blue">management requirements are Evaluation, Reporting, Review, Characteristics met unless process / procedure related to safety, Benefit-Risk, etc. indicates otherwise.</p></div><div class="question"><label>18.14. Determine the monitoring Set monitoring frequency for performance & drift</label><textarea placeholder="Provide details"></textarea><p style="color:blue">schedule for AI devices detection and user acceptance on an ongoing basis. (locked and unlocked, Define the duration of the monitoring (e.g., continual/continuous learning). continuous throughout the full lifecycle and frequency). Locked algorithms are subject to change though not at the same rate. A rationale should be provided for frequency and monitoring employed.</p></div><div class="question"><label>18.15. Identify if update is required to Assign responsibility for collecting and monitoring</label><textarea placeholder="Provide details"></textarea><p style="color:blue">performance logs, error logs, logs and results to maintain performance. drift monitoring metrics, etc.</p></div><div class="question"><label>18.16. Review post-market data for Identify safety signals linked to ML behaviour.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">feedback associated with this Ensure retraining schedule and model updates are device/change. adequate with rollback as needed. Document planned re-training schedule and method including method used for model updates. Provide reference to documents, such as maintenance plan or equivalent. Ensure versioning & traceability is maintained.</p></div></section>                                                                         <section id="section19"><h2>19. Clinical Risk Management (NHS Digital Health Guidance) ☐ N/A</h2><div class="question"><label>19.0. Does the change impact Clinical 
Risk Management (NHS)? If not indicate N/A and</label><textarea placeholder="Provide details"></textarea><p style="color:blue">leave remaining questions in this section blank. Provide rationale where a change is made to a UK product: Click or tap here to enter text.</p></div><div class="question"><label>19.1. Is an assessment of Clinical Yes, No. If no, provide rationale.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Risk Management: its application in the manufacture of Health IT Systems – Implementation Guidance, ID: NPFIT-FNT-TO-TOCLNSA- © N. St John Lynch, DkIT 2025-2026 Confidential Page 36 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01 1300.06 required for Refer to placement of this http://digital.nhs.uk/isce/publication/dcb0129 for device/health software on the recent / updated versions. UK market?</p></div><div class="question"><label>19.2. Is a clinical safety case report Yes, No. If no, provide rationale.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">required for full impact assessment of this change?</p></div></section>                                                                                                                                                             <section id="section20"><h2>20. Security Lifecycle (IEC-81001-5-1 2021) ☐ N/A</h2><div class="question"><label>20.0. Does the change impact security? If not, indica
te N/A and leave remaining questions in</label><textarea placeholder="Provide details"></textarea><p style="color:blue">this section blank. Provide rationale where a change is made without impact to security: Click or tap here to enter text.</p></div><div class="question"><label>20.1. Is the established security Security policy, responsibilities, risk ownership</label><textarea placeholder="Provide details"></textarea><p style="color:blue">governance process adequate to support this change with roles and responsibilities assigned?</p></div><div class="question"><label>20.2. Perform security risk analysis Identify threats, vulnerabilities, controls. Identify</label><textarea placeholder="Provide details"></textarea><p style="color:blue">including AI specific risk AI specific risks, including but not limited to: impacting security and Model poisoning, adversarial attacks, data protection. poisoning, drift and continuous- or continual- learning risks, explainability failures, model- update compromise or failure, inference pipeline DoS, bias risks, model theft, data, theft and misuse, synthetic data misuse.</p></div><div class="question"><label>20.3. Are the security requirements CIA (confidentiality, integrity, availability)</label><textarea placeholder="Provide details"></textarea><p style="color:blue">adequately defined and tested? requirements, regulatory considerations. State the regulations that are necessary to comply with and the methods required for testing or refer to documented plans/protocols.</p></div><div class="question"><label>20.4. Develop/review secure system Ensure Threat modelling is performed and</label><textarea placeholder="Provide details"></textarea><p style="color:blue">architecture for additional processes and procedures are in place to mitigate threats. vulnerabilities (e.g., privilege separation)</p></div><div class="question"><label>20.5. Are secure coding and Identify process/procedures for security code</label><textarea placeholder="Provide details"></textarea><p style="color:blue">development impacted by this review with static analysis. change?</p></div><div class="question"><label>20.6. Are existing security controls What has been reviewed/tested to ensure controls</label><textarea placeholder="Provide details"></textarea><p style="color:blue">adequate and verified? Are are acceptable e.g., pen-testing, security test new security controls evidence. required?</p></div><div class="question"><label>20.7. Is the secure release process Reference the processes in place for secure release</label><textarea placeholder="Provide details"></textarea><p style="color:blue">appropriate? and configuration maintenance and approval. © N. St John Lynch, DkIT 2025-2026 Confidential Page 37 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div><div class="question"><label>20.8. Are updates and patches Security advisories, vulnerability management plan</label><textarea placeholder="Provide details"></textarea><p style="color:blue">required to support this change?</p></div><div class="question"><label>20.9. Have credible field logs, Monitor field security reports, Incident response,</label><textarea placeholder="Provide details"></textarea><p style="color:blue">incident reports and supplier and monitoring logs. Review device reports and anomaly or device security lots security specialists, NIST, OWASP, etc. identified a risk that could impact this change?</p></div><div class="question"><label>20.10. Ensure risks with potential Identify threats, vulnerabilities, controls with</label><textarea placeholder="Provide details"></textarea><p style="color:blue">harm are escalated or traceable potential for harm to end user and ensure ISO to product level risk analysis. 14971 is met.</p></div></section>                                                                                                                         <section id="section21"><h2>21. Software / AI BOM (Bill of Materials) ☐ N/A</h2><div class="question"><label>21.0. Does the change impact BOM? If not, indicate N/A 
and leave remaining questions in</label><textarea placeholder="Provide details"></textarea><p style="color:blue">this section blank. Provide rationale where a change is made without impact to BOM: Click or tap here to enter text.</p></div><div class="question"><label>21.1. Identify SBOM / AIBOM SBOM and AIBOMs are necessary for security but</label><textarea placeholder="Provide details"></textarea><p style="color:blue">document ID version(s) are also valuable tools for identifying and risk assessing software and security related risks as well as applying SOUP controls per IEC 62304 where applicable.</p></div><div class="question"><label>21.2. Are new software/ AI ☐ Yes, provide reference: Click or tap here to enter text.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">components required to be ☐ No If no, provide rationale Click or tap here to enter added to S/AI BOM text.</p></div></section>                                               <section id="section22"><h2>22. Information Security, Cyber and Privacy Protection (IEC 27001) ☐ N/A</h2><div class="question"><label>22.0. Has an ISMS – Informatio
n Clause 4 Context; where an ISMS system is</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Security Management System established and is maintained, review ISMS policy been defined and certified? and process documentation for impact from changes specified. Ensure the scope of the ISMS is adequately defined, including boundaries and applicability. If an ISMS per IEC 27001 is not required, indicate section as N/A and move to next section (subsequent questions in this section can remain blank where N/A is indicated). © N. St John Lynch, DkIT 2025-2026 Confidential Page 38 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div><div class="question"><label>22.1. Is there an impact to the Clause 4 Context; understand the organisation</label><textarea placeholder="Provide details"></textarea><p style="color:blue">organisation and its context? and its context. Identify internal and external issues. What are the interfaces and dependencies between activities performed by the organisation (e.g., cloud computing) and those performed by other organisations? Evidence: provide a list of issues and content analysis.</p></div><div class="question"><label>22.2. Is there an impact to the Clause 4 Context; understand the needs of</label><textarea placeholder="Provide details"></textarea><p style="color:blue">stakeholders or needs of interested parties by identifying stakeholders and interested parties? their requirements. Evidence: provide stakeholder requirements document(s).</p></div><div class="question"><label>22.3. Is there a need for leadership Clause 5.1 Leadership; is a demonstration of top</label><textarea placeholder="Provide details"></textarea><p style="color:blue">understanding/acknowledgement management commitment necessary for this dependent on the criticality or change. If so, provide evidence: meeting minutes, nature of the change? leadership policy, statements or other. Refer to 5.1 for full list of methods of demonstration of leadership (i.e., policy, strategy, integration into organisation’s processes, resources, communication, targets/outcomes, effectiveness, promote improvement, support management).</p></div><div class="question"><label>22.4. Is there an impact to the ISMS Clause 5.2 Policy; is there an impact to the ISMS</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Policy? Policy or objectives; has the ISMS Policy been adequately defined? Is it available and communicated? Evidence: an approved ISMS policy shall be provided.</p></div><div class="question"><label>22.5. Is there an impact to Roles and Clause 5.3; are the ISMS roles and</label><textarea placeholder="Provide details"></textarea><p style="color:blue">responsibilities? responsibilities assignments documented? Evidence: role assignment matrix/ job specifications, escalation and approval matrices; report(s) on performance of ISMS provided to Top Management.</p></div><div class="question"><label>22.6. Has a Risk Assessment for ISMS Clause 6.1 Planning and Risk; has a risk</label><textarea placeholder="Provide details"></textarea><p style="color:blue">been performed to prevent, assessment process been defined and does it reduce undesired effects and require updating following this change? Apply achieve continual improvement? the risk assessment process to identify new or emerging risks and assess risk controls already defined? Evidence: risk assessment documents/report(s).</p></div><div class="question"><label>22.7. Are the risk acceptance criteria Clause 6.1.2 the IS risk assessment process must</label><textarea placeholder="Provide details"></textarea><p style="color:blue">adequate or impacted by this define a risk acceptance criterion for performing change? IS risk assessments, for consistent, valid and comparable results that is capable of identifying IS risks against loss of confidentiality, integrity and availability for information within the scope of the ISMS. Risk owners will also be identified © N. St John Lynch, DkIT 2025-2026 Confidential Page 39 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01 and security risks are analysed and evaluated with prioritisation for risk treatment.</p></div><div class="question"><label>22.8. Does the Risk Treatment Plan Clause 6.1.3 Risk Treatment: The Risk Treatment</label><textarea placeholder="Provide details"></textarea><p style="color:blue">(with adequate controls) require Process shall be planned and documented, with updating to the current State of treatment options suitable to the risks identified; the Art? suitable controls shall be implemented, e.g. collection of threat intelligence, inventory of assets and owners maintained, acceptable use and procedures for handling assets, information transfer rules, procedures or agreements, access control and rights, monitoring supplier services with agreements in place, control process for acquisition, use and exit from cloud services, incident planning, definition and communication with roles and responsibilities, etc. Ref. Annex A</p></div><div class="question"><label>22.9. Are objectives set impacted by Clause 6.2 Objectives and Planning. Objectives</label><textarea placeholder="Provide details"></textarea><p style="color:blue">this change? for Information Security (IS) should be set at relevant functions and levels. They should be consistent with the IS policy, be measurable (where practicable), be monitored, communicated, updated as appropriate and be available as documented information. Planning will include: what will be done, what resources are required, who is responsible, completion targets and results evaluated. All changes shall be carried out in a Planned Manner! Evidence: documented objectives and plans to achieve same.</p></div><div class="question"><label>22.10. Are the resources for IS Clause 7: determine and provide resources</label><textarea placeholder="Provide details"></textarea><p style="color:blue">impacted or additional necessary for establishing, maintaining and improving resources necessary? ISMS. Evidence: resource allocation records, job specifications, etc.</p></div><div class="question"><label>22.11. Is there an impact to or on Clause 7.2 Competence: competence of person(s)</label><textarea placeholder="Provide details"></textarea><p style="color:blue">competency arising from this doing the work related to IS shall be controlled change? and valid in terms of education, training or experience. Actions is necessary to correct any deficiencies (training, mentoring, re-assignment) and evaluate effectiveness of actions with records to demonstrate competency.</p></div><div class="question"><label>22.12. Is awareness training impacted or Clause 7.3 Awareness: person(s) doing the work</label><textarea placeholder="Provide details"></textarea><p style="color:blue">required? under IS shall be aware of policy, their contribution to effectiveness of ISMS and implications for failure to perform as per ISMS.</p></div><div class="question"><label>22.13. Is there a need for internal or Clause 7.4 Communication: a decision is</label><textarea placeholder="Provide details"></textarea><p style="color:blue">external communication for this necessary in terms of the internal / external change? communication(s) including, what is to be communicated, when, to whom and how. © N. St John Lynch, DkIT 2025-2026 Confidential Page 40 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div><div class="question"><label>22.14. Is there a need for creation or Clause 7.5 (7.5.1, -2, -3) Documented</label><textarea placeholder="Provide details"></textarea><p style="color:blue">change to documented Information. The organisation’s ISMS shall information? maintain relevant documentation as appropriate to their size, complexity and competency to ensure compliance and effectiveness of ISMS. Document Control procedures shall ensure maintenance is adequate (identification, description, format, suitable, adequate, available, protected, storage, etc.)</p></div><div class="question"><label>22.15. Are the operational processes Clause 8.1 Operational Planning and Control:</label><textarea placeholder="Provide details"></textarea><p style="color:blue">impacted or additional planning processes shall have established criteria and or controls necessary? implementing control of processes in accordance with the criteria. Documented information shall be available to the extent necessary to have confidence that the processes have been carried out as planned, including planned changes and review of consequences of unintended changes with mitigation for adverse effects.</p></div><div class="question"><label>22.16. Review and update as applicable Clause 8.2 IS Risk Assessment (on-going):</label><textarea placeholder="Provide details"></textarea><p style="color:blue">risk assessment at least for perform IS risk assessments at planned intervals significant changes or at planned or when significant changes are proposed or intervals and/or as defined per occur, taking account of the established criteria. policy/procedure(s). Evidence: Documented results.</p></div><div class="question"><label>22.17. Review and update Risk Clause 8.3 IS Risk Treatment (ongoing):</label><textarea placeholder="Provide details"></textarea><p style="color:blue">treatment plans. Implement the risk treatment plan and retain results.</p></div><div class="question"><label>22.18. Is there an impact to the Clause 9.1 Monitoring, measurement, analysis</label><textarea placeholder="Provide details"></textarea><p style="color:blue">monitoring, measurement, and evaluation (MMAE): the ISMS shall analysis and evaluation necessary document what needs to be monitored and to be performed as part of ISMS? measured, when and by whom, including security processes and controls; methods for same and ensure valid results (comparable and reproducible is necessary for validity. Evidence: results of MMAE.</p></div><div class="question"><label>22.19. Does the change impact the Clause 9.2 Internal Audit: perform internal audits</label><textarea placeholder="Provide details"></textarea><p style="color:blue">internal audit schedule or drive a at planned intervals to SOPs and IEC 27001 to need for a change to the audit demonstrate compliance and effectiveness. The activities? audit planning shall include frequency, methods, responsibilities, requirements and reporting. The importance of processes shall be considered as well as the previous audit findings. Audit criteria and scope shall be defined for each audit. Auditors selected shall be objective and impartial and reporting to relevant management. Evidence: retain records.</p></div><div class="question"><label>22.20. Is there an impact to Management Clause 9.3 Management Review (MR) should be</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Review? defined and performed at planned intervals to ensure continuing suitability, adequacy and effectiveness. See 9.3.2 and 9.3.3 for Review Inputs and Results. These include changes in external and internal issues relevant to ISMS, change in needs and expectations of interested parties under ISMS and more. Evidence: management review meeting minutes and report(s).</p></div><div class="question"><label>22.21. Is there an impact to continual Clause 10.1 Continual Improvement should be</label><textarea placeholder="Provide details"></textarea><p style="color:blue">improvement actions or documented with identification and activities? improvement. Evidence: improvement records/logs or results of review.</p></div><div class="question"><label>22.22. Is there a need to initiate a Clause 10.2 Nonconformity (NC) and CA.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">nonconformity and corrective Nonconformity shall be documented with action action (CA)? taken to control and correct, determine cause, assess potential for similar issues, etc. CA will be appropriate to the effects of NCs. Evidence: NC and CA records.</p></div><div class="question"><label>22.23. Adequate Controls Annex A: Appropriate evidence of adequate</label><textarea placeholder="Provide details"></textarea><p style="color:blue">controls should be demonstrated throughout the ISMS. Refer to full list under Annex A. These include but are not limited to Access Controls, Cryptography, Physical Security, Supplier Relationships.</p></div></section>                                                                               <section id="section23"><h2>23. Usability Analysis (ISO 32366-1, ISO 32366-3) ☐ N/A</h2><div class="question"><label>23.0. Does the change impact usability? If not,
 indicate N/A and leave remaining questions in</label><textarea placeholder="Provide details"></textarea><p style="color:blue">this section blank? Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>23.1. How has usability incorporated Include explainability, transparency,</label><textarea placeholder="Provide details"></textarea><p style="color:blue">AI-specific risks and interpretability, bias. requirements?</p></div><div class="question"><label>23.2. Are usability studies required to Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">support this change?</p></div><div class="question"><label>23.3. Are processes/procedures Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">adequately defined for usability to incorporate AI related medical devices. © N. St John Lynch, DkIT 2025-2026 Confidential Page 42 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div></section>                                                                                               <section id="section24"><h2>24. Safety & Performance and Deployment ☐ N/A</h2><div class="question"><label>24.0. Does the change impact safety and performance? If n
ot, indicate N/A and leave</label><textarea placeholder="Provide details"></textarea><p style="color:blue">remaining questions in this section blank? Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>24.1. What measures/ metrics Provide details. Provide rationale for the</label><textarea placeholder="Provide details"></textarea><p style="color:blue">are used to demonstrate appropriateness of use of the measures/metrics performance? chosen.</p></div><div class="question"><label>24.2. What claims are Provide details. Reference any IFU and</label><textarea placeholder="Provide details"></textarea><p style="color:blue">communicated to users promotional material(s) including web-site with about safety and version control. performance?</p></div><div class="question"><label>24.3. How will this change be Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">deployed to produce / clinical use?</p></div><div class="question"><label>24.4. How will this change be Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">communicated to users / stakeholders?</p></div></section>                                                                                                             <section id="section25"><h2>25. Post-market Performance Evaluation (clinical) ☐ N/A</h2><div class="question"><label>25.0. Does the change impact post-market perfor
mance? If not, indicate N/A and leave</label><textarea placeholder="Provide details"></textarea><p style="color:blue">remaining questions in this section blank? Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>25.1. Is there a change to post- Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">market plan(s), surveillance or monitoring to support this change?</p></div><div class="question"><label>25.2. How is this change Provide details. How can this change be checked in</label><textarea placeholder="Provide details"></textarea><p style="color:blue">monitored in use? post-production phase for safety and effectiveness?</p></div><div class="question"><label>25.3. What level of human Provide details. Reference monitoring protocols,</label><textarea placeholder="Provide details"></textarea><p style="color:blue">oversight (human in the PMS plans, etc. loop) is applied to this device and/or change?</p></div></section>                                                                                                                                         <section id="section26"><h2>26. Pre-determined Change Control Plan ☐ N/A</h2><div class="question"><label>26.0. Does the change impact PCCP? If not, indicate N/A an
d leave remaining questions in</label><textarea placeholder="Provide details"></textarea><p style="color:blue">this section blank? Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>26.1. Is there an Authorised Yes/No, if Yes, define in what markets and regulatory</label><textarea placeholder="Provide details"></textarea><p style="color:blue">PCCP in place? authorities have review/approved the PCCP. © N. St John Lynch, DkIT 2025-2026 Confidential Page 43 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01 Has this change been included in the scope of the authorised PCC? If yes, provide location/specific detail as to how it is included.</p></div><div class="question"><label>26.2. Will this change Yes/No. Provide details. Identify all documents</label><textarea placeholder="Provide details"></textarea><p style="color:blue">support/change a new or required for creation / update of PCCP for an authorised PCCP regulatory approval. necessary to be reviewed by regulatory authority?</p></div></section>                                                                <section id="section27"><h2>27. Post-market Software Monitoring, Logging and Reporting ☐ N/A</h2><div class="question"><label>27.0. Does the change impact monitorin
g, logging, reporting? If not, indicate N/A and leave</label><textarea placeholder="Provide details"></textarea><p style="color:blue">remaining questions in this section blank? Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>27.1. What level of access is Provide details. Reference, monitoring or</label><textarea placeholder="Provide details"></textarea><p style="color:blue">available to software maintenance and vulnerability plan(s). developers/ engineers/ legal manufacturer for monitoring, logging and reporting?</p></div><div class="question"><label>27.2. How is the data reviewed, Provide details. Reference procedures or plan(s) as</label><textarea placeholder="Provide details"></textarea><p style="color:blue">reported? applicable.</p></div><div class="question"><label>27.3. Is the reporting, Provide details. Reference procedures or plan(s) as</label><textarea placeholder="Provide details"></textarea><p style="color:blue">communication strategy applicable. adequate for the device including this change to the device?</p></div></section>                                                      <section id="section28"><h2>28. EU AI Act Regulation 2024/1689 (as amended) ☐N/A</h2><div class="question"><label>28.0. Indicate if the AI Act Regulatory Requiremen
ts for Medical Devices is required? If</label><textarea placeholder="Provide details"></textarea><p style="color:blue">not, check N/A and leave the remaining questions blank.</p></div><div class="question"><label>28.1. Identify the intended purpose Article 8 stipulates that high-risk AI systems under</label><textarea placeholder="Provide details"></textarea><p style="color:blue">of the AI device/components the AI Act 2024/1689 must be subject to AI Act and identify if this is different rules and regulations. Under the proposed change from the intended purpose dated 16 Dec 2025, we have adopted the refined stated above for the product. changes assuming adoption in 2026, where they remove duplication and negative impact from overly burdensome regulatory frameworks, innovation and cost. According to the proposed changes, Chapter III, Section will be applicable to High-Risk AI systems, such as regulated AIeMD. They adopt horizontal requirements that reflect © N. St John Lynch, DkIT 2025-2026 Confidential Page 44 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01 those already set out in MDR/IVDR 2017/745 and 2017/746 regulations.</p></div><div class="question"><label>28.2. Article 9 – Risk Management Risk Management shall comply with the ISO 14971</label><textarea placeholder="Provide details"></textarea><p style="color:blue">product and AI requirements already set out in this document. In additional fundamental rights are also included and should be considered as part of risk management ref. (Lynch et al. 2026).</p></div><div class="question"><label>28.3. Article 10 – Data and Data Data used shall meet quality criteria and shall be</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Governance subject to data governance and management practices. This is reflected in the sections above. Examination of biases is highlighted in relation to fundamental rights and must be examined. Training, validation and test data sets shall be relevant, sufficiently representative and to the best extent possible, free of errors and complete in view of the intended purpose. Data sets shall take into account, geographical, contextual, behavioural, or functional setting in relations to intended use.</p></div><div class="question"><label>28.4. Article 11 – Technical Technical documentation shall be drawn up and</label><textarea placeholder="Provide details"></textarea><p style="color:blue">documentation maintained up to date. A single set of technical documents shall be drawn up under the MDR/IVDR (not a separate set for AI regulatory compliance).</p></div><div class="question"><label>28.5. Article 12 – Record keeping Recording of logging for post-market surveillance</label><textarea placeholder="Provide details"></textarea><p style="color:blue">shall be implemented. Logging capabilities should provide the recording period of each use of the system (start date, and time and end date and time of each use), database against which input data was checked by the system, input data for which the search led to a match and identification of the persons involved in the verification of the results.</p></div><div class="question"><label>28.6. Article 13 – Transparency and Transparency shall enable deployers to interpret</label><textarea placeholder="Provide details"></textarea><p style="color:blue">provision of information to systems output and use it appropriately. IFU shall deployers contain at least the identity and contact details of the prover or authorised representative, the characteristics, capabilities and limitations of performance, the intended purpose, level of accuracy and metrics used for robustness and cybersecurity (refer Article 15) against which the system has been tested and validated and what can be expected – known and foreseeable circumstances that may impact accuracy, robustness and cybersecurity as well as residual risks, technical capabilities and characteristics to explain the output.</p></div><div class="question"><label>28.7. Article 14 – Human oversight Ensure the system can be overseen by human-in the</label><textarea placeholder="Provide details"></textarea><p style="color:blue">loop in order to prevent or minimise risk to health, © N. St John Lynch, DkIT 2025-2026 Confidential Page 45 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01 safety or fundamental rights that may emerge. This shall be commensurate with the risk, level of autonomy and context. The persons performing such oversight will be aware of the capacities, limitations and potential to rely or over-rely on output as well as provision of tools to support interpretation of outputs correctly.</p></div><div class="question"><label>28.8. Article 15 – Accuracy, Achieve appropriate level of accuracy, robustness</label><textarea placeholder="Provide details"></textarea><p style="color:blue">robustness and cybersecurity and cybersecurity to perform consistently throughout their lifecycle. Address technical methods to measure same. Declare in IFU. Technical and organisation measures for resilience to failures and errors shall be taken. Feedback loops or appropriate measures are adopted for continuous/continual learning system. Security risks are mitigated as identified above. Security shall address measures to prevent, detect, respond, resolve and control attacks.</p></div></section>                                                   <section id="section29"><h2>29. Sustainability ☐ N/A</h2><div class="question"><label>29.0. Does the change impact the sustainability policy or requirements? If not
, indicate N/A</label><textarea placeholder="Provide details"></textarea><p style="color:blue">and leave remaining questions in this section blank? Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>29.1. Have requirements been Provide details. Reference procedures or plan(s) as</label><textarea placeholder="Provide details"></textarea><p style="color:blue">determined for sustainability applicable. Review the EU AI Act (2024), Ecodesign objectives? for Sustainable products Regulation ESPR, 2024 and the Corporate Sustainability Due Diligence Directive, CSDDD, 2024. Identify guidance or requirements published for energy-efficiency standards and sustainable AI design that are applicable to AI-enabled medical devices (AIeMD). Identify policy or procedures for sustainability incorporated by the organisation.</p></div><div class="question"><label>29.2. How does this change support Provide details. Reference procedures or plan(s) as</label><textarea placeholder="Provide details"></textarea><p style="color:blue">sustainability objectives? applicable.</p></div></section>                               <section id="section30"><h2>30. Technical Documentation, DMR and DHR ☐ N/A</h2><div class="question"><label>30.0. Does the change impact technical documentation? If
 not, indicate N/A and leave</label><textarea placeholder="Provide details"></textarea><p style="color:blue">remaining questions in this section blank? Provide rationale: Click or tap here to enter text. © N. St John Lynch, DkIT 2025-2026 Confidential Page 46 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div><div class="question"><label>30.1. Is the Device History Record Provide details</label><textarea placeholder="Provide details"></textarea><p style="color:blue">(DHR) impacted by this change?</p></div><div class="question"><label>30.2. Is the Device Master Record Provide details</label><textarea placeholder="Provide details"></textarea><p style="color:blue">(DHR) impacted by this change?</p></div><div class="question"><label>30.3. Are the Product History Records Provide details</label><textarea placeholder="Provide details"></textarea><p style="color:blue">or Templates impacted by this change?</p></div><div class="question"><label>30.4. Is the Declaration of Conformity Provide details</label><textarea placeholder="Provide details"></textarea><p style="color:blue">impacted by this change?</p></div><div class="question"><label>30.5. Has the technical documentation Provide details</label><textarea placeholder="Provide details"></textarea><p style="color:blue">been updated with full traceability to this change?</p></div></section>                                                                              <section id="section31"><h2>31. Checklist of Deliverables arising from this Change ☐ N/A</h2><div class="question"><label>31.0. Is a checklist for deliverables requ
ired to support this change? If not, indicate N/A and</label><textarea placeholder="Provide details"></textarea><p style="color:blue">leave remaining questions in this section blank? Provide rationale: Click or tap here to enter text. Based on the review performed, identify the deliverables necessary to review/updates required for completion prior to implementation of change described.</p></div><div class="question"><label>31.1. Risk Management File ☐ n/a Provide details</label><textarea placeholder="Provide details"></textarea><p style="color:blue"></p></div><div class="question"><label>31.2. Dataset Inventory and Data ☐ n/a Provide details</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Quality Report</p></div><div class="question"><label>31.3. AI Model Card and ☐ n/a Provide details</label><textarea placeholder="Provide details"></textarea><p style="color:blue">reproducibility package</p></div><div class="question"><label>31.4. Test Protocols and Reports ☐ n/a Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue"></p></div><div class="question"><label>31.5. Maintenance Plan / ☐ n/a Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Vulnerability Management Plan</p></div><div class="question"><label>31.6. Cybersecurity risk assessment, ☐ n/a Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">mitigation and response plan</p></div><div class="question"><label>31.7. Vulnerability Management Plan ☐ n/a Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue"></p></div><div class="question"><label>31.8. Post-market surveillance and ☐ n/a Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">monitoring Plan</p></div><div class="question"><label>31.9. User documentation, IFU, ☐ n/a Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">training materials, labelling, limitations and intended use</p></div><div class="question"><label>31.10. Clinical evidence ☐ n/a Provide details. Study protocols, results</label><textarea placeholder="Provide details"></textarea><p style="color:blue">and statistical analysis</p></div><div class="question"><label>31.11. PCCP documents ☐ n/a Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">© N. St John Lynch, DkIT 2025-2026 Confidential Page 47 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div><div class="question"><label>31.12. Other: Click or tap here to enter ☐ n/a Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">text. Add additional rows as required</p></div></section>                                                                             <section id="section32"><h2>32. Regulatory Approval and Conformity Assessment / Certification ☐ N/A</h2><div class="question"><label>32.0. Is a regulatory review re
quired to support this change? If not, indicate N/A and leave</label><textarea placeholder="Provide details"></textarea><p style="color:blue">remaining questions in this section blank? Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>32.1. Regulatory Assessment of ☐ Significant Change</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Change for Significance/ reporting ☐ Non-Significant Change ☐ Note to File / QMS Change to be notified to authorities at next Recertification/Surveillance Audit Is this change deemed significant and if so, what authorities require reporting prior to implementation of the change, where PCCP does not already cover the scope of this change? Provide rationale: Click or tap here to enter text.</p></div><div class="question"><label>32.2. Is a new conformity Provide details.</label><textarea placeholder="Provide details"></textarea><p style="color:blue">assessment required by regulatory body (FDA, Notified Body, other)?</p></div><div class="question"><label>32.3. Has regulatory approval been ☐ Yes, via Authorised PCCP – change is included in</label><textarea placeholder="Provide details"></textarea><p style="color:blue">granted for this change scope. ☐ Yes, via Authorised PCCP – change not included in scope – updated authorised PCCP required ☐ Yes, granted and attached as a significant change. ☐ Yes, pending approval; change to regulatory approval is required prior to implementation. ☐ No, approval is not required – minor change only with Note to file or equivalent as per Quality/AI Management System ☐ Attach or reference file/location with approval: © N. St John Lynch, DkIT 2025-2026 Confidential Page 48 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div><div class="question"><label>32.4. Have minimum AI Yes, minimum thresholds maintained</label><textarea placeholder="Provide details"></textarea><p style="color:blue">performance thresholds been reviewed and maintained as No, minimum thresholds are not maintained and documented by regulatory communication is necessary to relevant stakeholders authority? Provide list of minimum thresholds reviewed and maintained: e.g., Accuracy (mean, macro, etc.), Sensitivity (recall), Specificity, F1, AUC, etc.</p></div><div class="question"><label>32.5. Are all relevant regulations and ☐ EU AI Act</label><textarea placeholder="Provide details"></textarea><p style="color:blue">standards addressed and ☐ MDR 2017/745 General Safety and ☐ IVDR 2017/746 Performance Requirements ☐ Accessibility checklists (GSPR) or Essential ☐ Interoperability Requirements (ER) or relevant ☐ Data Protection compliance documents updated ☐ Security accordingly? ☐ RED Add others as appropriate to territory and device type</p></div><div class="question"><label>32.6. Is an update required to the Provide reference to DoC document(s) review/updated</label><textarea placeholder="Provide details"></textarea><p style="color:blue">Declaration of Conformity and provide rationale if update is not deemed (DoC) for the AIeMD? necessary.</p></div></section>                                                                                                                                    <section id="section33"><h2>33. Change Approval to Implement ☐ N/A</h2><div class="question"><label>33.0. Is approval required under this form? If not, indicate N/A
 and identify method for</label><textarea placeholder="Provide details"></textarea><p style="color:blue">approval of change. Click or tap here to enter text. This form can be used as a supplemental checklist as part of an existing eQMS with change control, where approval is documented within the eQMS itself. Role Name Signature Date Author(s) e-signature is equivalent to wet (ink) signature Regulatory Affairs e-signature is equivalent to wet (ink) signature Quality Assurance e-signature is equivalent to wet (ink) signature Clinical/Medical e-signature is equivalent to wet (ink) signature Software Lead e-signature is equivalent to wet (ink) signature AI Governance Officer e-signature is equivalent to wet (ink) signature Data Protection Officer e-signature is equivalent to wet (ink) signature © N. St John Lynch, DkIT 2025-2026 Confidential Page 49 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01 Other Click or tap here to enter ☐ n/a Provide details. text. to wet (ink) signature Add rows as required</p></div></section>                                                                             <section id="section34"><h2>34. Implementation & Effectiveness Plan ☐ N/A</h2><div class="question"><label>34.0. Is an effectiveness plan required? If not, indicate
 N/A and identify method for</label><textarea placeholder="Provide details"></textarea><p style="color:blue">effectiveness checking of changes. Click or tap here to enter text.</p></div><div class="question"><label>34.1. Define Implementation Plan define or reference relevant change plan/ quality plan</label><textarea placeholder="Provide details"></textarea><p style="color:blue">and Targets or AI / Software Development plan with a list of tasks/activities required to complete this change including identification of assigned owners and target dates. A Gantt chart may support this deliverable.</p></div><div class="question"><label>34.2. Are any change management Provide details. For example, Process Assessment</label><textarea placeholder="Provide details"></textarea><p style="color:blue">maturity assessments used to Model (PAM) (e.g., ISO/IEC 30105-2:2024) or support improved projects, Process Reference Models (e.g., MDevSPICE®) – e.g., project safety and PD performance evaluation of devices performance? demonstrates high performance and safety profile as documented within Management Review’s assessment of internal audits, complaints, data analysis, etc.</p></div><div class="question"><label>34.3. Identify effectiveness planning Document or reference how the change will be</label><textarea placeholder="Provide details"></textarea><p style="color:blue">and method for tracking to assessed for effectiveness and accomplishment of completion. suitable QMS/AI governance objectives and procedures.</p></div><div class="question"><label>34.4. Target date for completion dd/mmm/yyyy</label><textarea placeholder="Provide details"></textarea><p style="color:blue">© N. St John Lynch, DkIT 2025-2026 Confidential Page 50 of 55 AIeMD Change CR No.: 0001 Management Assessment Template No.: TMP-001 Revision 01</p></div></section>                                                                                                                              <section id="section35"><h2>35. Appendix: Additional Guidance</h2></section>
<section id="section36"><h2>36. References</h2></section>
        </section>
    </main>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mammoth/1.4.2/mammoth.browser.min.js"></script>
    <script src="script.js"></script>
</body>
</html>